SOR102 vs SPY003

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

SOR102

Developed by Sorriso Pharmaceuticals

Phase 1 in Ulcerative ColitisBiologic (oral dual TNFα/IL-23(p19) inhibitor)
Weak signal

NCT06080048 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Treatment Emergent Adverse Events following oral dosing". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Treatment Emergent Adverse Events following oral dosing (Up to 6 weeks in Part 3 or at the time of study discontinuation): First-in-human phase 1. Part 1 (healthy participants): treatment-emergent adverse events in 3/24 (13%) receiving SOR102 versus 2/8 (25%) receiving placebo. Part 2: no treatment-emergent adverse events in the 10 participants receiving twice-daily SOR102. Part 3 (ulcerative colitis patients): at least one adverse event in 7/16 (44%) treated with SOR102 and 3/6 (50%) receiving placebo. Rates of clinical response ranged from 29% to 67%, depending on the definition applied.

Result source: NCT06080048

SPY003

Developed by Spyre Therapeutics

Phase 2 in Ulcerative Colitismonoclonal antibody (anti-IL-23)
Partial signal

NCT07012395 · Phase 2 · recruiting

This was a randomized, quadruple-masked Phase 2 trial with 645 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-08. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: June 2027 · NCT07012395 (registry estimate)

Reported efficacy

Part A: Change in Robarts Histopathology Index (RHI) (Week 12); Part B: Percentage of participants with clinical remission (Week 12): Part A primary endpoint (week 12): Robarts Histopathology Index reduced 10.0 points from baseline (p<0.0001) (Spyre, 2026-09-08). (met)

Result source: NCT07012395

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSOR102SPY003
Clinical remission (induction)—Not reported—Not reported
Clinical remission (maintenance)—Not reported—Not reported
Clinical response (induction)—Not reported—Not reported
Endoscopic improvement (induction)—Not reported—Not reported
Corticosteroid-free remission (maintenance)—Not reported—Not reported

Clinical remission (induction)

SOR102
—Not reported
SPY003
—Not reported

Clinical remission (maintenance)

SOR102
—Not reported
SPY003
—Not reported

Clinical response (induction)

SOR102
—Not reported
SPY003
—Not reported

Endoscopic improvement (induction)

SOR102
—Not reported
SPY003
—Not reported

Corticosteroid-free remission (maintenance)

SOR102
—Not reported
SPY003
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SOR102: no structured comparison results are available for Ulcerative Colitis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

SPY003
Part A primary endpoint (week 12): Robarts Histopathology Index reduced 10.0 points from baseline (p<0.0001) (Spyre, 2026-09-08). NCT07012395 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SOR102's landscape · SPY003's landscape